"We are very pleased to have reached this agreement with Royalty Pharma. Remicade® is not only a clear example of the importance and quality of the research conducted by NYU's scholars, it is also a significant source of support for the School of Medicine's and University's academic and research enterprise. Remicade® is a prime example of how bench research can be translated to provide benefits to millions of patients."
Robert Berne, Senior Vice President for Health, New York University
At a Glance
Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn's Disease, Ulcerative Colitis
REMICADE® was the first anti-TNF-alpha treatment to be approved in three different therapeutic areas: gastroenterology, rheumatology and dermatology. REMICADE® has demonstrated broad clinical utility with indications in Crohn's disease (CD), rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), ulcerative colitis (UC), pediatric Crohn's disease (PCD) and psoriasis (PsO). The safety and efficacy of REMICADE® have been well established in clinical trials over the past seventeen years and through commercial experience with more than one million patients treated worldwide.
REMICADE® is unique among available anti-TNF biologic therapies. It is the only anti-TNF biologic administered directly by caregivers in the clinic or office setting. REMICADE® is a two-hour infusion administered every 4 or 8 weeks (indication-dependent), following a standard induction regimen that requires treatment at weeks 0, 2 and 6. As a result, REMICADE® patients may require as few as six treatments each year as maintenance therapy.
Applications In Development:
anti-TNF (Immunology), Juvenile Rheumatoid Arthritis